KPC Pharmaceutical's 2025 Profit Slips 46%

MT Newswires Live

02/06

KPC Pharmaceutical (SHA:600422) recorded an attributable profit of 349.9 million yuan for the year 2025, down 46% from 648.1 million yuan a year prior, according to a Friday Hong Kong bourse filing by parent China Resources Pharmaceutical Group (HKG:3320).

Basic EPS stood at 0.46 yuan for the year, down from 0.86 yuan in the last corresponding period.

Operating revenue for the period slipped 22% to 6.58 billion yuan from 8.4 billion yuan in the year-ago period.

The downbeat results came about amid a decline in product sales and gross profit margin.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2609953235"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609953235\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609953235?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 20:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609953235","market":"hk","top_or_hot":-1,"title":"KPC Pharmaceutical's 2025 Profit Slips 46%","media":"MT Newswires Live","content":"<html><body><p> KPC Pharmaceutical (SHA:600422) recorded an attributable profit of 349.9 million yuan for the year 2025, down 46% from 648.1 million yuan a year prior, according to a Friday Hong Kong bourse filing by parent China Resources Pharmaceutical Group (HKG:3320).</p><p>Basic EPS stood at 0.46 yuan for the year, down from 0.86 yuan in the last corresponding period.</p><p>Operating revenue for the period slipped 22% to 6.58 billion yuan from 8.4 billion yuan in the year-ago period.</p><p>The downbeat results came about amid a decline in product sales and gross profit margin.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KPC Pharmaceutical's 2025 Profit Slips 46%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKPC Pharmaceutical's 2025 Profit Slips 46%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-06 20:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> KPC Pharmaceutical (SHA:600422) recorded an attributable profit of 349.9 million yuan for the year 2025, down 46% from 648.1 million yuan a year prior, according to a Friday Hong Kong bourse filing by parent China Resources Pharmaceutical Group (HKG:3320).</p><p>Basic EPS stood at 0.46 yuan for the year, down from 0.86 yuan in the last corresponding period.</p><p>Operating revenue for the period slipped 22% to 6.58 billion yuan from 8.4 billion yuan in the year-ago period.</p><p>The downbeat results came about amid a decline in product sales and gross profit margin.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1570","symbol_name":"华润系","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2609953235","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609953235","pubTimestamp":1770382498,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"KPC Pharmaceutical  recorded an attributable profit of 349.9 million yuan for the year 2025, down 46% from 648.1 million yuan a year prior, according to a Friday Hong Kong bourse filing by parent China Resources Pharmaceutical Group .Basic EPS stood at 0.46 yuan for the year, down from 0.86 yuan in the last corresponding period.Operating revenue for the period slipped 22% to 6.58 billion yuan from 8.4 billion yuan in the year-ago period.The downbeat results came about amid a decline in product sales and gross profit margin.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600422":"昆药集团","BK1570":"华润系","03320":"华润医药","BK0060":"抗癌","BK1191":"制药","BK0028":"国家队","BK0239":"医药制造","BK0188":"融资融券"},"translate_title":"KPC制药2025年利润下滑46%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600422":0.9,"03320":1},"content_text":"KPC Pharmaceutical (SHA:600422) recorded an attributable profit of 349.9 million yuan for the year 2025, down 46% from 648.1 million yuan a year prior, according to a Friday Hong Kong bourse filing by parent China Resources Pharmaceutical Group (HKG:3320).Basic EPS stood at 0.46 yuan for the year, down from 0.86 yuan in the last corresponding period.Operating revenue for the period slipped 22% to 6.58 billion yuan from 8.4 billion yuan in the year-ago period.The downbeat results came about amid a decline in product sales and gross profit margin.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}